logo

Galectin Therapeutics Inc (GALT)



Trade GALT now with
  Date
  Headline
5/10/2019 8:06:14 AM Galectin Therapeutics Q1 Loss Applicable To Holders Of $9.1 Mln Or $0.20/Shr Vs Loss $4.5 Mln Or $0.12/shr Last Year
12/20/2018 8:36:06 AM Galectin Therapeutics Announces Extension Of $10 Mln Line Credit
11/13/2018 8:24:00 AM Galectin Therapeutics Q3 Net Loss Applicable To Common Stockholders $3.0 Mln Or $0.07 Per Share
9/20/2018 8:04:32 AM Galectin Therapeutics Announces Positive Preliminary Results From Phase 1b Clinical Trial Of GR-MD-02 And KEYTRUDA
8/14/2018 8:08:17 AM Galectin Therapeutics Q2 Loss Applicable To Stockholders $4.1 Mln Or $0.11/Shr Vs Loss $4.8 Mln Or $0.14/Shr Last Year
6/27/2018 8:05:38 AM Galectin Therapeutics Receives Patent For GR-MD-02 Patent For Method And Treatment Of Pulmonary Fibrosis
6/12/2018 8:37:23 AM Galectin Therapeutics Names Harold Shlevin CEO And President To Succeed Peter Traber
6/4/2018 9:13:19 AM Galectin Therapeutics Elects Richard Uihlein As Chairman Of Board Of Directors
5/14/2018 9:05:50 AM Galectin Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis Following FDA Meeting
5/11/2018 4:26:11 PM Galectin Therapeutics Q1 Loss/share $0.12 Vs. Loss $0.15 Year Ago